Celularity Secures $35M Strategic License Deal

Biotech firm strengthens capital position to advance longevity-focused strategy.

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Celularity Inc., a biotech company, has entered into a strategic commercialization partnership for its placental-derived biomaterials portfolio. The transaction is expected to generate up to $35 million in upfront and milestone payments for Celularity. The company has granted an exclusive license to its commercial-stage biomaterials portfolio and certain development-stage programs.

Why it matters

This deal provides Celularity with non-dilutive capital to advance its longevity-focused strategy, leveraging its expertise in placental-derived biomaterials. The partnership also secures an ongoing manufacturing revenue stream for Celularity while maintaining participation in the economics of the licensed products.

The details

Under the agreement, Celularity will act as the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions.

  • The transaction is expected to close no later than April 15, 2026.

The players

Celularity Inc.

A biotech company focused on developing placental-derived biomaterials and therapies.

Got photos? Submit your photos here. ›

The takeaway

This strategic partnership strengthens Celularity's capital position and allows the company to continue advancing its longevity-focused initiatives using its proprietary placental-derived biomaterials technology.